PMID- 32691850
OWN - NLM
STAT- MEDLINE
DCOM- 20210219
LR  - 20210219
IS  - 1600-0404 (Electronic)
IS  - 0001-6314 (Print)
IS  - 0001-6314 (Linking)
VI  - 142
IP  - 6
DP  - 2020 Dec
TI  - Eslicarbazepine acetate in post-stroke epilepsy: Clinical practice evidence from 
      Euro-Esli.
PG  - 563-573
LID - 10.1111/ane.13323 [doi]
AB  - OBJECTIVES: To assess the effectiveness and safety/tolerability of 
      eslicarbazepine acetate (ESL) in patients included in the Euro-Esli study who had 
      focal seizures associated with post-stroke epilepsy (PSE). MATERIALS AND METHODS: 
      Euro-Esli was a pooled analysis of 14 European clinical practice studies. 
      Effectiveness assessments (evaluated after 3, 6 and 12 months of ESL treatment 
      and at final follow-up ["last visit"]) included rates of response (>/=50% seizure 
      frequency reduction), seizure freedom (no seizures since at least the prior 
      visit) and retention. Safety/tolerability was assessed throughout ESL treatment 
      by evaluating adverse events (AEs) and discontinuation due to AEs. A post hoc 
      analysis was conducted of patients with PSE versus patients without PSE 
      ("non-PSE"). RESULTS: Of 1656 patients included in the analysis, 76 (4.6%) had 
      PSE and 1580 (95.4%) had non-PSE. Compared with non-PSE patients, PSE patients 
      were significantly older, had significantly shorter epilepsy duration, 
      significantly lower total baseline seizure frequency, and were treated with 
      significantly fewer prior and concomitant antiepileptic drugs (P < .001 for all). 
      At the last visit, the responder rate was significantly higher in PSE versus 
      non-PSE patients (72.9% vs 60.6%; P = .040), as was the seizure freedom rate 
      (48.6% vs 31.7%; P = .003). After 12 months, retention was significantly higher 
      in PSE versus non-PSE patients (87.8% vs 77.4%; P = .035). The incidence of AEs 
      was similar for PSE versus non-PSE patients (36.0% vs 35.8%; P = .966). 
      CONCLUSIONS: These findings suggest that ESL may be an effective and 
      well-tolerated treatment option for patients with focal seizures due to PSE.
CI  - (c) 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Sales, Francisco
AU  - Sales F
AUID- ORCID: 0000-0003-0834-066X
AD  - Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal.
FAU - Chaves, Joao
AU  - Chaves J
AD  - Department of Neurology, Hospital Santo Antonio, Centro Hospitalar Porto, Porto, 
      Portugal.
FAU - McMurray, Rob
AU  - McMurray R
AD  - Eisai Europe Ltd, Hatfield, UK.
FAU - Loureiro, Rui
AU  - Loureiro R
AD  - Bial - Portela & C feminine, S.A., Coronado, Portugal.
FAU - Fernandes, Helder
AU  - Fernandes H
AUID- ORCID: 0000-0003-0898-932X
AD  - Bial - Portela & C feminine, S.A., Coronado, Portugal.
FAU - Villanueva, Vicente
AU  - Villanueva V
AD  - Hospital Universitario y Politecnico La Fe, Valencia, Spain.
LA  - eng
GR  - Bial - Portela & C feminine, S.A./
GR  - Eisai/
PT  - Journal Article
DEP - 20200812
PL  - Denmark
TA  - Acta Neurol Scand
JT  - Acta neurologica Scandinavica
JID - 0370336
RN  - 0 (Anticonvulsants)
RN  - 0 (Dibenzazepines)
RN  - BEA68ZVB2K (eslicarbazepine acetate)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticonvulsants/adverse effects/*therapeutic use
MH  - Dibenzazepines/adverse effects/*therapeutic use
MH  - Epilepsy/*drug therapy/*etiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Seizures/prevention & control
MH  - Stroke/*complications
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC7754143
OTO - NOTNLM
OT  - Epilepsy
OT  - eslicarbazepine acetate
OT  - seizures
OT  - stroke
COIS- FS has received speaker's honoraria and/or consultancy fees from Bial and Eisai. 
      JC has received speaker's honoraria and/or consultancy fees from Bial and Eisai, 
      and a research bursary from Tecnifar. RM is a current employee of Eisai Europe 
      Ltd. RL and HF are current employees of Bial - Portela & C feminine, SA. VV has 
      participated in advisory boards and pharmaceutical industry-sponsored symposia 
      for Eisai, UCB Pharma, Bial, Pfizer, GSK, Esteve, Novartis and GW Pharma.
EDAT- 2020/07/22 06:00
MHDA- 2021/02/20 06:00
PMCR- 2020/12/22
CRDT- 2020/07/22 06:00
PHST- 2020/05/11 00:00 [received]
PHST- 2020/07/13 00:00 [revised]
PHST- 2020/07/16 00:00 [accepted]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/12/22 00:00 [pmc-release]
AID - ANE13323 [pii]
AID - 10.1111/ane.13323 [doi]
PST - ppublish
SO  - Acta Neurol Scand. 2020 Dec;142(6):563-573. doi: 10.1111/ane.13323. Epub 2020 Aug 
      12.